Literature DB >> 10651600

Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.

B G Yangco1, J C Von Bargen, A C Moorman, S D Holmberg.   

Abstract

BACKGROUND: HIV-infected patients with sustained immunologic improvement from antiretroviral therapy may be able to discontinue chemoprophylaxis against Pneumocystis carinii pneumonia (PCP).
OBJECTIVE: To compare PCP incidence in HIV-infected patients who had sustained CD4+ lymphocyte counts greater than 200 cells/mm3 and who either discontinued or continued PCP prophylaxis.
DESIGN: Nonrandomized prospective cohort study.
SETTING: 10 HIV clinics in eight U.S. cities. PATIENTS: 146 patients had follow-up visits for a mean of 18.2 months after discontinuation of PCP prophylaxis, and 345 patients who continued PCP prophylaxis had follow-up visits for a mean of 14.0 months. MEASUREMENTS: Incidence of PCP.
RESULTS: Patients who discontinued PCP prophylaxis had higher maximum and minimum CD4+ cell counts and lower vira loads than patients who continued PCP prophylaxis. Pneumocystis carinii pneumonia did not develop in either group (upper 95% exact binomial confidence limit of incidence for those who discontinued PCP prophylaxis, 2.3/100 person-years).
CONCLUSIONS: Discontinuation of PCP chemoprophylaxis may be appropriate for some HIV-infected ambulatory patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651600     DOI: 10.7326/0003-4819-132-3-200002010-00005

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  HIV Treatment in Developing Countries.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

2.  2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

Authors: 
Journal:  Infect Dis Obstet Gynecol       Date:  2002

3.  Functional impairment of CD4 T cells despite normalization of T cell number in HIV.

Authors:  Kenneth S Knox; Richard B Day; Lisa M Kohli; Chadi A Hage; Homer L Twigg
Journal:  Cell Immunol       Date:  2006-10-30       Impact factor: 4.868

4.  Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  Chien-Yu Cheng; Mao-Yuan Chen; Szu-Min Hsieh; Wang-Huei Sheng; Hsin-Yun Sun; Yi-Chun Lo; Wen-Chun Liu; Chien-Ching Hung
Journal:  BMC Infect Dis       Date:  2010-05-21       Impact factor: 3.090

Review 5.  Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?

Authors:  Christoph G Lange; Ian J Woolley; Reinhard H Brodt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  The HIV Outpatient Study-25 Years of HIV Patient Care and Epidemiologic Research.

Authors:  Kate Buchacz; Carl Armon; Frank J Palella; Richard M Novak; Jack Fuhrer; Ellen Tedaldi; Douglas Ward; Cynthia Mayer; Linda Battalora; Kimberly Carlson; Stacey Purinton; Marcus Durham; Jun Li
Journal:  Open Forum Infect Dis       Date:  2020-04-11       Impact factor: 3.835

7.  Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral Therapy Era.

Authors:  Hansjakob Furrer
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.663

Review 8.  Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.

Authors:  Cecilia T Costiniuk; Dean A Fergusson; Steve Doucette; Jonathan B Angel
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.